Client Result
Orrick Advises Ipsen on Acquisition of Epizyme
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
April.21.2022
Congratulations to our client Convoy on its $260 million funding round which will accelerate the development of its efficiency-focused technologies.
1 minute read | October.22.2021
Orrick advised VNV Global and Kinnevik in their investments in Babylon's $4.2 billion de-SPAC transaction.
October.20.2021
Orrick has advised Turn/River Capital on its investment in Invicti Security’s $625 million funding round, led by Summit Partners.
October.07.2021
Orrick advised Apex Clean Energy in the sale of a majority stake in the company to funds and other accounts managed by Ares Management.
September.15.2021
Congratulations to our client Sizewise Rentals on its definitive agreement to be acquired by Agiliti for $230 million.
September.15.2021
September.09.2021
Congratulations to our client Scalapay on its $155 million Series A funding round, led by Tiger Global.
August.25.2021
July.14.2021
June.25.2021
June.18.2021
We are advising disruptive AgTech company Local Bounti on its definitive agreement to become publicly traded via a SPAC merger with Leo Holdings.